Advanced Oncotherapy (AVO)

 

AVO Share PerformanceMore

52 week high217.25 04/01/16
52 week low58.00 02/12/16
52 week change -75.88 (-56.47%)
4 week volume3,307,878 07/11/16

Media for (AVO)

Presenter: Nicolas Serandour
12/10/2016

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Operational Update

RNS Number: 5987Q Advanced Oncotherapy PLC 30 November 2016 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Operational Update Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, provides additional clarification surrounding the update provided on 24 N...

Director Deals - Advanced Oncotherapy PLC (AVO)

Dr Enrico Vanni, Non Executive Director, bought 75,000 shares in the company on the 28th November 2016 at a price of 6...

Director Dealing - replacement

RNS Number: 4437Q Advanced Oncotherapy PLC 29 November 2016 The following amendment has been made to the 'Director Dealing' announcement released today at 10:06 under RNS No 4275Q. Following the transaction, Dr Vanni now holds 673,946 Ordinary Shares representing 0.93% of the issued share capital of the Company, and not '637,000' shares representin...

Director Dealing

RNS Number: 4275Q Advanced Oncotherapy PLC 29 November 2016 29 November 2016 Advanced Oncotherapy plc (" Advanced Oncotherapy " or the "Company") Director Dealing Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed yesterday that Dr Enrico Vanni, a...

Update on Harley Street and Sinophi

RNS Number: 1149Q Advanced Oncotherapy PLC 24 November 2016 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Update on Harley Street and Sinophi Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the building work for the Harley Street sit...

Holding(s) in Company

RNS Number: 2689P Advanced Oncotherapy PLC 15 November 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Advanced Oncotherapy Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of votin...

Advanced Oncotherapy appoints joint broker

Advanced Oncotherapy has appointed Stifel Nicolaus Europe as joint broker to the company, with immediate effect. Stock...

Change of Adviser

RNS Number: 5478O Advanced Oncotherapy PLC 08 November 2016 8 November 2016 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Appointment of Joint Broker Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Stifel Nicolaus E...

Fundamental DataMore

EPS-0.51
Dividend yield0 %

Equity Research (AVO)

hardman & co
Advanced Oncotherapy Plc
02/11/2016
AVO is focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN. Planning Permission for its...
Advanced Oncotherapy Plc
01/11/2016
Eco Animal Health (EAH.L) 495p £317.9m The specialist in the development, registration and marketing of pharmaceutical products for animals has received a marketing authorisation from the Thailand...
hardman & co
Advanced Oncotherapy Plc
28/10/2016
AVO is focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN. Planning Permission for its...

Latest discussion posts More

  • Beaufort Securities' view

    Update from Beaufort Securities https://www.research-tree.com/research/breakfast-today/7841a173-b3ee-4a79-8c7d-e2d8973ecec4
    2-Dec-2016
    Sambram
  • Re: What's up again ?

    I work in a similar industry and, agreed, it is now the key milestone. The RNS stated that we'll get an update in Q1 next year, that gives them plenty of wriggle room, as I ...
    1-Dec-2016
    fish lips
  • Re: What's up again ?

    Fish lips it shows they read the bulletin boards. You mentioned the testing in a previous post. I agree this is an area that investors will be focusing on in the future. It's ...
    1-Dec-2016
    Meanbugger

Users' HoldingsMore

Users who hold Advanced Oncotherapy also hold..
LLOYDS GRP.20%
SIRIUS MINERALS14%
TAYLOR WIMPEY14%
ID:ISIN:GB00BD8GDH8613%
VODAFONE GRP.11%

Codes & Symbols

ISINGB00BD6SX109
SymbolsAVO, LSE:AVO, AVO.L, AVO:LN, LON:AVO, XLON:AVO